Robuta

https://www.fiercebiotech.com/biotech/ocugen-climbs-phase-3-covid-vaccine-data-hitting-back-at-delta-variant Ocugen climbs on phase 3 COVID vaccine data, hitting back at delta variant | Fierce Biotech Jul 6, 2021 - After seeing its stock fall consistently over the past few months, Ocugen and partner Bharat Biotech have posted some encouraging data from their pandemic... https://www.prnewswire.co.uk/news-releases/ocugen-reports-positive-phase-2-clinical-results-demonstrating-proof-of-concept-for-its-novel-677363503.html Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel... /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and... https://www.fiercebiotech.com/keyword/ocugen Ocugen | Fierce Biotech ocugenfiercebiotech https://www.nasdaq.com/market-activity/stocks/ocgn/news-headlines Ocugen, Inc. Common Stock (OCGN) News Headlines | Nasdaq Stay up-to-date on Ocugen, Inc. Common Stock (OCGN) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com. common stocknews headlinesocugenincocgn https://www.home.saxo/nl-be/markets/stocks/ocgn-xnas Ocugen Inc. aandeel | Saxo Bank Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for... ocugenincaandeelsaxobank https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-secures-financial-runway-as-gene-therapy-pipeline-accelerates/69111799 Ocugen Secures Financial Runway as Gene Therapy Pipeline Accelerates Ocugen's gene therapy pipeline advances with Phase 3 data due in 2027, $12.33 avg price target, and funding secured into 2027 despite a $67.8M net loss. gene therapy pipelineocugensecuresfinancialrunway https://www.macrotrends.net/stocks/charts/OCGN/ocugen/net-income Ocugen Net Income 2013-2025 | OCGN | MacroTrends Ocugen net income from 2013 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been... net incomeocugen20132025ocgn https://www.fool.com/investing/2021/04/22/why-ocugen-and-nikola-are-powering-the-nasdaq-high/ Why Ocugen and Nikola Are Powering the Nasdaq Higher | The Motley Fool Apr 22, 2021 - Favorable news from two key sectors helped support the broader market. ocugennikola https://theorg.com/org/ocugen/teams/regulatory-and-compliance-team Ocugen - Regulatory and Compliance Team | The Org The Regulatory and Compliance Team at Ocugen is responsible for ensuring that all biopharmaceutical products meet industry regulations and quality standards... regulatory and complianceocugenteam https://theorg.com/org/ocugen/teams/finance-and-administration-team Ocugen - Finance and Administration Team | The Org The Finance and Administration Team at Ocugen is responsible for overseeing the company's financial health and strategic planning. finance and administrationocugenteam https://www.home.saxo/nb-no/markets/stocks/ocgn-xnas Ocugen Inc. aksje | Saxo Bank Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for... ocugenincaksjesaxobank https://www.nasdaq.com/market-activity/stocks/ocgn/sec-filings Ocugen, Inc. Common Stock (OCGN) SEC Filings | Nasdaq Find the latest SEC Filings data for Ocugen, Inc. Common Stock (OCGN) including 10-K and 10-Q forms at Nasdaq.com. common stocksec filingsocugenincocgn https://www.entrepreneur.com/business-news/despite-an-80-drop-ocugen-stock-is-still-too-pricey/420021 Despite an 80% Drop, Ocugen Stock Is Still Too Pricey despite80dropocugenstock https://www.home.saxo/da-dk/markets/stocks/ocgn-xnas Ocugen Inc. aktie | Saxo Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for... ocugenincaktiesaxo https://theorg.com/org/ocugen/offices/hq Ocugen - HQ | The Org Ocugen's headquarters in Malvern, PA, United States ocugenhq https://www.fool.com/investing/2021/12/19/better-buy-ocugen-vs-pfizer/ Better Buy: Ocugen vs. Pfizer | The Motley Fool Dec 19, 2021 - Can they both win in the coronavirus vaccine space? better buyocugenvspfizermotley https://www.marketscreener.com/news/ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes-ce7f58dcdb8ff622 Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes | MarketScreener May 5, 2026 - Ocugen Inc: Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes ... https://www.biospace.com/press-releases/ocugen-inc-announces-first-patient-dosed-in-phase-2-3-gardian3-pivotal-confirmatory-trial-for-ocu410st-novel-modifier-gene-therapy-candidate-for-stargardt-disease Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for... https://www.biospace.com/ocugen-to-present-at-investing-in-cures-summit Ocugen to Present at Investing in Cures Summit - BioSpace Aug 7, 2024 - Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures... investing inocugenpresentcuressummit https://finbold.com/guide/how-to-buy-ocgn-stock-invest-in-ocugen/ How to Buy OCGN stock | Invest in Ocugen Jan 1, 2025 - Discover how to buy Ocugen stock and tap into the potential of gene and cell therapies for eye-related conditions. how to buystock investocgnocugen https://www.biospace.com/ocugen-provides-business-update-and-third-quarter-2020-financial-resultsfirst-gene-therapy-candidate-ocu400-on-track-to-enter-the-clinic-in-2021 Ocugen Provides Business Update and Third Quarter 2020 Financial ResultsFirst Gene Therapy... Nov 6, 2020 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to cure blindness... business updatethird quarter https://www.fool.com/investing/2021/03/07/heres-the-biggest-problem-ocugen-faces-right-now/ Here's the Biggest Problem Ocugen Faces Right Now | The Motley Fool Mar 7, 2021 - This point will determine just how much Ocugen can profit from its potential coronavirus vaccine. here sthe biggestright nowproblem https://investingnews.com/ocugen-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference-biotech-on-tap-2025/ Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap... Sep 11, 2025 - Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr.... https://investorplace.com/2021/08/ocgn-stock-odds-firmly-against/ OCGN Stock: The Odds Are Firmly Against Ocugen Now | InvestorPlace Aug 27, 2021 - OCGN stock is a remarkably risky Covid-19 vaccine play, as the company faces a myriad of regulatory roadblocks on different fronts. the oddsocgnstockfirmlyocugen https://www.finanznachrichten.de/aktien-analysen/ocugen-inc.htm OCUGEN-AKTIE kaufen? Analysen, Kursziele & Empfehlungen zu A2PSZH OCUGEN-Aktie jetzt kaufen? Analysen und Kursziele: aktie kaufenocugenanalysenkurszieleempfehlungen https://www.finanznachrichten.de/nachrichten-2026-04/68101770-ocugen-announces-early-completion-of-dosing-in-phase-2-3-pivotal-confirmatory-trial-of-ocu410st-for-stargardt-disease-399.htm Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for... GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST... https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-aktie-blick-nach-vorn/68416425 Ocugen Aktie: Blick nach vorn Der Biotech-Spezialist Ocugen stellt seine Pipeline vor und bereitet sich auf wichtige klinische und regulatorische Schritte im kommenden Jahr vor, darunter... ocugenaktieblicknachvorn https://www.fool.com/earnings/call-transcripts/2021/05/07/ocugen-inc-ocgn-q1-2021-earnings-call-transcript/ Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript | The Motley Fool May 8, 2021 - OCGN earnings call for the period ending March 31, 2021. earnings call transcriptocugenincocgnq1 https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-ocugen-microvision-marathon-digital-casper-sleep-or-riot-blockchain-301276689.html Thinking about buying stock in Ocugen, Microvision, Marathon Digital, Casper Sleep, or Riot... /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, MVIS, MARA, CSPR, and RIOT. To see how InvestorsObserver's proprietary scoring... https://www.biospace.com/clinical-catch-up-developments-in-parkinson-s-mcrc-covid-19-cystic-fibrosis-candidates Clinical Catch-Up: Neuron23, QIAGEN, Ocugen, BMS and More - BioSpace Sep 30, 2024 - There's a new collaboration in the Parkinson's disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen... catch upand moreclinicalqiagenocugen https://investingnews.com/ocugen-provides-business-update-with-first-quarter-2026-financial-results/ Ocugen Provides Business Update with First Quarter 2026 Financial Results | INN May 5, 2026 - Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a... business updatefirst quarterfinancial resultsocugenprovides https://www.biospace.com/ocugen-inc-to-present-at-2023-bio-ceo-and-investor-conference Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference - BioSpace Jan 31, 2023 - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell... investor conferenceocugenincpresent https://www.fool.com/investing/2021/11/21/battle-of-the-covid-vaccine-contenders-inovio-vs-o/ Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen | The Motley Fool Nov 21, 2021 - Both vaccine makers still have big hurdles to jump. battle ofcovid vaccine https://www.biospace.com/ocugen-to-participate-in-panel-at-cantor-fitzgerald-global-healthcare-conference-2023 Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 - BioSpace Aug 7, 2024 - Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual... https://www.macrotrends.net/stocks/charts/OCGN/ocugen/gross-margin Ocugen Gross Margin 2013-2025 | OCGN | MacroTrends Current and historical gross margin for Ocugen (OCGN) over the last 10 years. The current gross profit margin for Ocugen as of December 31, 2025 is... gross marginocugen20132025ocgn https://www.fool.com/investing/2021/12/15/why-ocugen-stock-jumped-today/ Why Ocugen Stock Jumped Today | The Motley Fool Dec 15, 2021 - Results from a study suggest that Covaxin could be effective in coronavirus variants of concern. ocugenstockjumpedtodaymotley https://theorg.com/org/ocugen/teams/leadership-team Ocugen - Leadership Team | The Org The Leadership Team at Ocugen drives the strategic vision and operational direction of the company, focusing on innovation in gene therapies for blindness and... leadership teamocugen https://investingnews.com/ocugen-inc-announces-positive-scientific-advice-from-the-european-medicines-agency-related-to-the-approval-pathway-for-ocu410st-modifier-gene-therapy-for-stargardt-disease/ Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the... Sep 11, 2025 - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...